Connealy Pamela Ann 4

What Happened

• Pamela Ann Connealy, a director of Orchestra BioMed Holdings, was awarded equity compensation on June 23, 2026: 17,327 restricted stock units (RSUs) and 21,277 derivative awards reported as a separate grant. Both grants were reported at $0.00 per share (no cash paid) and total 38,604 units. These awards are grants (compensation), not purchases or sales.

Key Details

• Transaction date: 2026-06-23; price reported: $0.00 per unit.
• Award breakdown: 17,327 RSUs (F1) and 21,277 derivative awards (F2 — described as stock options).
• Vesting: Both the RSUs and the stock options vest on the one‑year anniversary of the grant (June 23, 2027), subject to Connealy's continuous service through that date.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Report filed 2026-06-25 for a 2026-06-23 grant — appears to be timely (filed within typical two-business-day window).
• No tax‑withholding, sales, or cashless exercises were reported in the provided data.

Context

• RSUs represent a contingent right to receive one share at vesting; the awarded RSUs will convert to common stock only if vesting conditions are met. The derivative award (per F2) appears to be stock options that also vest in one year and would require exercise to become shares.
• These are compensation grants to a board member and are common for aligning management/director interests with shareholders; they are not the same signal as open‑market purchases by insiders.